Nasus Pharma Says FDA Cleared IND Application For NS002 Intranasal Epinephrine Powder In Anaphylaxis; Plans Pivotal Study In Q4 2026, Topline Data In Q1 2027

Benzinga Newsdesk www.benzinga.com Neutral 50.3%

Neg 0% Neu 50.3% Pos 0%

Comments

No comments yet. Be the first!